Frederick S Barrett1, Matthew W Johnson1, Roland R Griffiths1,2. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine. 2. Department of Neuroscience, Johns Hopkins University School of Medicine.
Abstract
OBJECTIVES: Classic hallucinogens (e.g. psilocybin and LSD) have substantial effects on perception, cognition, and emotion that can often be psychologically challenging, however we know very little regarding the source of significant individual variability that has been observed in the frequency and intensity of challenging experiences (i.e. "bad trips") with psychedelics. Previous clinical and observational literature suggests that there may be an association between neuroticism and challenging psychedelic experiences. METHODS: Data from two online surveys of challenging experiences with psilocybin were analyzed. Multivariate analysis was used to estimate the associations between total score and scores from seven sub-factors (fear, grief, physical distress, insanity, isolation, death, and paranoia) of the Challenging Experience Questionnaire (CEQ), and scale scores from the Ten Item Personality Inventory (TIPI) in Study 1 (N=1993) and the Big Five Inventory (BFI) in Study 2 (N = 981). RESULTS: CEQ scores were negatively associated with emotional stability scores (the inverse of neuroticism) in Study 1 and positively associated with neuroticism scores in Study 2. CONCLUSIONS: Neuroticism may contribute to the strength of challenging experiences in uncontrolled settings.
OBJECTIVES:Classic hallucinogens (e.g. psilocybin and LSD) have substantial effects on perception, cognition, and emotion that can often be psychologically challenging, however we know very little regarding the source of significant individual variability that has been observed in the frequency and intensity of challenging experiences (i.e. "bad trips") with psychedelics. Previous clinical and observational literature suggests that there may be an association between neuroticism and challenging psychedelic experiences. METHODS: Data from two online surveys of challenging experiences with psilocybin were analyzed. Multivariate analysis was used to estimate the associations between total score and scores from seven sub-factors (fear, grief, physical distress, insanity, isolation, death, and paranoia) of the Challenging Experience Questionnaire (CEQ), and scale scores from the Ten Item Personality Inventory (TIPI) in Study 1 (N=1993) and the Big Five Inventory (BFI) in Study 2 (N = 981). RESULTS:CEQ scores were negatively associated with emotional stability scores (the inverse of neuroticism) in Study 1 and positively associated with neuroticism scores in Study 2. CONCLUSIONS: Neuroticism may contribute to the strength of challenging experiences in uncontrolled settings.
Entities:
Keywords:
bad trips; challenging experiences; hallucinogen; individual differences; neuroticism
Authors: Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths Journal: J Psychopharmacol Date: 2016-11-17 Impact factor: 4.153
Authors: Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman Journal: J Psychopharmacol Date: 2015-01-13 Impact factor: 4.153
Authors: Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths Journal: J Psychopharmacol Date: 2016-08-30 Impact factor: 4.153
Authors: Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt Journal: J Psychopharmacol Date: 2016-12 Impact factor: 4.153
Authors: Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt Journal: Lancet Psychiatry Date: 2016-05-17 Impact factor: 27.083
Authors: William E Rosa; Zachary Sager; Megan Miller; Ilan Bernstein; Alden Doerner Rinaldi; Katie Addicott; Michael Ljuslin; Chris Adrian; Anthony L Back; Jamie Beachy; Anthony P Bossis; William S Breitbart; Mary P Cosimano; Stacy M Fischer; Jeffrey Guss; Emma Knighton; Janis Phelps; Brian D Richards; William A Richards; James A Tulsky; Monnica T Williams; Yvan Beaussant Journal: J Palliat Med Date: 2022-03-14 Impact factor: 2.947
Authors: Christopher Timmermann; Leor Roseman; Luke Williams; David Erritzoe; Charlotte Martial; Héléna Cassol; Steven Laureys; David Nutt; Robin Carhart-Harris Journal: Front Psychol Date: 2018-08-15
Authors: Lukasz Smigielski; Michael Kometer; Milan Scheidegger; Rainer Krähenmann; Theo Huber; Franz X Vollenweider Journal: Sci Rep Date: 2019-10-24 Impact factor: 4.379
Authors: Eline C H M Haijen; Mendel Kaelen; Leor Roseman; Christopher Timmermann; Hannes Kettner; Suzanne Russ; David Nutt; Richard E Daws; Adam D G Hampshire; Romy Lorenz; Robin L Carhart-Harris Journal: Front Pharmacol Date: 2018-11-02 Impact factor: 5.810